This has led to the conceptualization of a symptom-agnostic, biomarker-based classification system called the Amyloid-β/Tau/Neurodegeneration [AT(N)] system, which stratifies individuals upon core pathophysiological changes in AD [154]. The gene discussed is MAPT; the disease is Alzheimer disease.